The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq].
| Target |
AKT1 |
| Reactivity |
Human, Mouse |
| Host |
Rabbit |
| Clonality |
Polyclonal |
| Tested Applications |
WB, IHC, IF/ICC, FCM |
| Recommended dilutions |
Optimal dilutions/concentrations should be determined by the end user. |
| Immunogen |
KLH-conjugated synthetic peptide between 428-457 amino acids from the C-terminal region of human AKT1. |
| Purification |
Purified through a protein A column, followed by peptide affinity purification. |
| Isotype |
IgG |
| Conjugation |
Unconjugated |
| Storage |
Aliquot and store at -20 °C. Avoid repeated freeze/thaw cycles. |
| Swiss Prot |
P31749
|
| Buffer |
PBS containing 0.09% sodium azide. |
| UNSPSC Code |
12352203 |
| Availability |
Shipped within 5-10 working days. |
| Note |
This product is for research use only. |